LTC Nursing Care Plan – Parkinson's Disease (PD) Psychosis

Concerns & Problems	Resident/Family Nursing Goals	Assessment Date	Nonpharmacologic and/or Pharmacologic Interventions	Responsible Discipline	Reevaluation	Tean Initia
Symptoms:	Resident/Family:		Assessment/systematic observation ² :		At 30 Days:	
/ I Hallucinations¹:	☐ Stabilization, reduction, or remission of		☐ Identify problems through assessments of symptoms			_
Eg, seeing or	symptoms/episodes		\square Assess the history and consequences of			-
nearing things that are	☐ Decreased intensity of		symptoms			-
not there	symptoms/episodes ☐ Increase/preserve social interaction		☐ Clarify who is negatively affected			-
			Ascertain causes for symptoms ² :		At 60 Days:	
			\square Resident has negative view of caregiver			-
	Nursing:		☐ Resident doesn't understand intent of caregiver			-
Delusions¹: Eg, paranoia	☐ Engage in activities of daily living (ADLs)		☐ Resident is suffering from social isolation or sensory deprivation			-
	☐ Participate in PT/OT/ST		☐ Resident misinterprets situations			-
	as ordered to promote overall functioning and psychosocial well-being		Conduct intervention matching causes of symptoms, resident's habits and preferences, and current abilities ^{2,3} :		At 90 Days:	-
Observable behaviors:	☐ Maintain safe		☐ Music therapy			_
	environment		☐ Orientation training			-
	☐ Monitor risk for falls		☐ Exercise			-
	☐ Other		☐ Art-cognitive activity		Quarterly:	
			Intervention addressed to ² :			_
			☐ Resident			-
			☐ Environment			-
			☐ Staff member			_
			☐ Family		PRN:	
			Assess and reevaluate whether symptoms and quality of life have improved post-intervention ²			_
			Pharmacologic Interventions⁴: ☐ Administer medications per order ☐ Observe for effectiveness of medications			- - -
			☐ Observe for adverse reactions			
			☐ Missed/refused medications			
			Consult healthcare provider for any drug/dose changes			

Under CMS F657 a **comprehensive care plan** must be developed within 7 days after completion of the comprehensive assessment. This care plan should be prepared by an interdisciplinary team that includes, but is not limited to, the attending physician, a registered nurse with responsibility for the resident, a nurse aide with responsibility for the resident, a member of food and nutrition services staff, and, to the extent practicable, the resident, the resident's representatives, and other appropriate staff or professionals in disciplines determined by the resident's needs or as requested by the resident. This care plan should be reviewed and revised by the interdisciplinary team after each assessment, including the comprehensive and quarterly review assessments.⁵

Additional notes:							

This planning tool is provided by ACADIA for educational purposes only. Please use your clinical judgment for establishing a full comprehensive nursing care plan for patients with Parkinson's Disease Psychosis.

This tool has been approved by:



For additional information regarding PD psychosis, please visit www.moretoparkinsons.com.

References: 1. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061-1068.

2. Cohen-Mansfield J. Nonpharmacologic interventions for psychotic symptoms in dementia. J Geriatr Psychiatry Neurol. 2003;16(4):219-224.

3. Chen R, Liu C, Lin M, et al. Non-pharmacological treatment reducing not only behavioral symptoms, but also psychotic symptoms of older adults with dementia: a prospective cohort study in Taiwan. Geriatr Gerontol Int. 2014;14(2):440-446.

4. Dunlop SR, Gerstenhaber M. Long-term care and nursing home issue. In: Menza M, Marsh L, eds. Psychiatric Issues in Parkinson's Disease: A Practical Guide. New York, NY: Informa Healthcare USA, Inc; 2009.

5. US Centers for Medicare & Medicaid Services. State Operations Manual Pub 100-07. Appendix PP - Guidance to Surveyors for Long Term Care Facilities. Baltimore, MD: US Dept of Health and Human Services; 2017.

©2020 ACADIA Pharmaceuticals Inc.

ACADIA is a registered trademark of ACADIA Pharmaceuticals Inc. All rights reserved. PDP-0599-v3 06/20.